Review
Pharmacology & Pharmacy
Beata Biri-Kovacs, Zoltan Banoczi, Anitha Tummalapally, Ildiko Szabo
Summary: Skin cancer is the most common type of cancer, with melanoma being a leading cause of skin cancer deaths. Recent advancements in understanding melanoma tumorigenesis and its interaction with the immune system have led to the development of new therapeutic strategies. Peptide-based vaccines, which target tumor antigens and activate immune responses, have shown promise in treating advanced melanoma. However, the immunogenicity of peptide antigens can be enhanced through synthetic modifications, adjuvants, and delivery systems. This review summarizes the various chemical approaches for developing effective peptide-based vaccines for immunotherapy in advanced melanoma.
Article
Oncology
Takafumi Yanagisawa, Akihiro Matsukawa, Kosuke Iwatani, Shun Sato, Yasushi Hayashida, Yohei Okada, Takashi Yorozu, Wataru Fukuokaya, Keigo Sakanaka, Fumihiko Urabe, Shoji Kimura, Shunsuke Tsuzuki, Masayuki Shimoda, Hiroyuki Takahashi, Jun Miki, Shahrokh F. Shariat, Takahiro Kimura
Summary: This study compared the impact of en bloc resection of bladder tumors (ERBT) with conventional transurethral resection of bladder tumors (cTURBT) on high-grade bladder cancer. The results showed that both surgeries had similar perioperative and mid-term oncologic outcomes. However, ERBT improved the quality of resection and specimen, resulting in less residue on repeat transurethral resection and better histopathologic information.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Immunology
Maoyu Wang, Zhensheng Zhang, Zhizhou Li, Yasheng Zhu, Chuanliang Xu
Summary: With the increasing incidence of bladder cancer, there has been a focus on understanding its mechanism and developing new treatment strategies. The introduction of immune checkpoint inhibitor-based immunotherapy has shown great promise in treating advanced bladder cancer and improving patients' survival. The ubiquitin-proteasome system, which plays a crucial role in various biological processes, has been found to be involved in bladder cancer. This review summarizes the recent progress in understanding the role of E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and highlights their implications for bladder cancer immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Alexander J. Stephens, Nicola A. Burgess-Brown, Shisong Jiang
Summary: Peptide-based cancer vaccines rely on strong activation of adaptive immune response but have not yet proven to be effective in clinical settings. To overcome limitations, vaccine designs are becoming more personalized and combined with existing cancer treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Veterinary Sciences
Ana Mafalda Rasteiro, Eva Sa e Lemos, Paula A. Oliveira, Rui M. Gil da Costa
Summary: Bladder cancer in veterinary medicine, particularly in companion animals, is still poorly understood but recent advances in identifying tumor markers and introducing targeted therapies have shown promise. This review focuses on small animal oncology and provides an update on the field, drawing comparisons with bladder cancer in humans and experimental models of the disease.
VETERINARY SCIENCES
(2022)
Article
Immunology
Fatemeh Zahedipour, Khadijeh Jamialahmadi, Parvin Zamani, Mahmoud Reza Jaafari
Summary: Peptide vaccines have shown potential in cancer immunotherapy by targeting tumor antigens and activating the immune system, but their efficacy is still a major challenge. This review discusses the current status and strategies to improve the efficacy of peptide vaccines, including the use of novel adjuvants, neoantigens, nano-delivery systems, and combination therapies. Personalized cancer vaccines, multivalent peptides, conjugated peptides, fusion proteins, and self-assembled peptides are also highlighted as ways to enhance the immunogenicity of peptide vaccines. Combining peptide vaccines with other immunotherapeutic approaches and developing personalized vaccines can significantly improve their efficacy and clinical outcomes for cancer patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Andre L. De Souza, Anthony E. Mega, John Douglass, Adam J. Olszewski, Ece D. Gamsiz Uzun, Alper Uzun, Charissa Chou, Fenghai Duan, Jinyu Wang, Amin Ali, Dragan J. Golijanin, Sheldon L. Holder, Galina G. Lagos, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro
Summary: Despite new therapies, advanced urothelial carcinoma still has a poor prognosis. FGFR2 and FGFR3 mutations, PD-L1 expression, tumor mutational burden, and microsatellite instability are predictive biomarkers. Novel biomarkers can improve treatment sequencing and outcomes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Ines Lecoq, Katharina L. Kopp, Marion Chapellier, Panagiotis Mantas, Evelina Martinenaite, Maria Perez-Penco, Lars Ronn Olsen, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen
Summary: This study identified CCL22 as a potential target for immunotherapy by showing that vaccination with CCL22-derived peptides induced specific T-cell responses and had anti-tumor effects in mouse models. The vaccination also modulated the immune cell composition in the tumor microenvironment, increasing the infiltration of CD8+ cells and M1 macrophages, and altering the immune cell ratios. These findings provide a rationale for the development of CCL22-targeting immunotherapy in cancer.
Article
Veterinary Sciences
Kathryn E. Cronise, Sunetra Das, Belen G. Hernandez, Daniel P. Regan, Deanna D. Dailey, Robert McGeachan, Susan E. Lana, Rodney L. Page, Daniel L. Gustafson, Dawn L. Duval
Summary: Transitional cell carcinoma is the most common type of bladder cancer in humans and dogs, with high metastatic risk. Canine transitional cell carcinoma serves as a model for evaluating novel therapies for human muscle-invasive TCC. Molecular characterization revealed a high prevalence of BRAF variants in canine TCC, suggesting potential therapeutic targets for both human and canine cancers.
VETERINARY AND COMPARATIVE ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Houhong Zhou, Lei Zhang, Weihan Luo, Huaishan Hong, Dongdong Tang, Dewang Zhou, Lingli Zhou, Yuqing Li
Summary: In this study, the expression of the innate immune sensor AIM2 is found to be lower in high-grade BLCA and positively correlates with the survival rates of the BLCA patients. Overexpression of AIM2 can delay tumor growth and enhance the therapeutic effect of BCG in BLCA.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Shengming Jin, Han Zeng, Zhaopei Liu, Kaifeng Jin, Chunnan Liu, Sen Yan, Yanze Yu, Runze You, Hongyi Zhang, Yuan Chang, Le Xu, Jiejie Xu, Zewei Wang, Yu Zhu
Summary: Stromal-infiltrating tumor-associated macrophages (TAMs) have clinical significance in muscle-invasive bladder cancer (MIBC), serving as a prognostic indicator and potentially guiding precise treatments.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Immunology
Alireza Tojjari, Ahmed Saeed, Meghana Singh, Ludimila Cavalcante, Ibrahim Halil Sahin, Anwaar Saeed
Summary: This review examines the potential of cancer vaccines as a novel therapeutic approach for hepatocellular carcinoma (HCC). The authors discuss different types of cancer vaccines, their role and challenges in HCC treatment. They highlight clinical trials and future perspectives, emphasizing the importance of personalized therapies, novel antigen delivery platforms, and predictive biomarkers.
Article
Biochemistry & Molecular Biology
Wen-Su Wei, Ning Wang, Min-hua Deng, Pei Dong, Jian-ye Liu, Zhen Xiang, Xiang-Dong Li, Zhi-yong Li, Zhen-hua Liu, Yu-lu Peng, Zhen Li, Li-Juan Jiang, Kai Yao, Yun-lin Ye, Wen-hua Lu, Zhi-Ling Zhang, Fang-Jian Zhou, Zhuo-Wei Liu, Dan Xie, Chun-ping Yu
Summary: LRPPRC plays critical roles in regulating UCB redox homeostasis and tumorigenesis by modulating ROS balance, mt-mRNA metabolism, and the circANKHD1/FOXM1 axis to protect UCB cells from oxidative stress. Additionally, LRPPRC is a prognostic factor for UCB and may be a therapeutic target in UCB.
Article
Immunology
Huihuang Li, Xiongbing Zu, Jiao Hu, Zicheng Xiao, Zhiyong Cai, Ning Gao, Jinbo Chen
Summary: This study found that different cuproptosis patterns in bladder cancer patients are associated with tumor microenvironment phenotypes and immunotherapy efficacy. By constructing a cuproptosis risk score and signature, it is possible to accurately predict patient prognosis and immunotherapy efficacy.
FRONTIERS IN IMMUNOLOGY
(2022)